Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Tumor Biology

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-011-0237-7PMID 21931992
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

  2011cited by this paper
• Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.

  2009cited by this paper
• Dysregulation of apoptosis in hepatocellular carcinoma cells.

  2009cited by this paper
• Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response

  2009cited by this paper
• Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications.

  2009cited by this paper
• A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma

  2009cited by this paper
• Diagnosis and treatment of hepatocellular carcinoma.

  2008cited by this paper
• Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer

  2008cited by this paper
• Treatment of hepatocellular carcinoma.

  2006cited by this paper
• Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.

  2006cited by this paper
• Early and Specific Prediction of the Therapeutic Efficacy in Non–Small Cell Lung Cancer Patients by Nucleosomal DNA and Cytokeratin‐19 Fragments

  2006cited by this paper
• Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation.

  2006cited by this paper
• Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

  2006cited by this paper
• Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.

  2005cited by this paper
• Chemoembolization for hepatocellular carcinoma.

  2004cited by this paper
• Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

  2004cited by this paper
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  2003cited by this paper
• Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

  2003cited by this paper
• Factors predictive of 5‐year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma

  2003cited by this paper
• Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

  2002cited by this paper
• Hepatocellular Carcinoma in Southern Germany: Epidemiological and Clinicopathological Characteristics and Risk Factors

  2002cited by this paper
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

  2001cited by this paper
• Nucleosomes in Serum as a Marker for Cell Death

  2001cited by this paper
• Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.

  2001cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001cited by this paper
• Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma.

  2000cited by this paper
• A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization

  2000cited by this paper
• Rising incidence of hepatocellular carcinoma in the United States.

  1999cited by this paper
• Colon tumor precursors identified by magnifying endoscopy

  1999cited by this paper
• Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution

  1998cited by this paper
• Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

  1998cited by this paper
• Chemoembolization in hepatocellular carcinoma.

  1998cited by this paper
• Treatment of hepatocellular carcinoma

  1997cited by this paper
• A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.

  1995cited by this paper
• Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies.

  1993cited by this paper
• Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

  1993cited by this paper

• Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab

  2025cites this paper
• Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C-related Hepatocellular Carcinoma Among Egyptians: A Prospective Study.

  2024cites this paper
• Arterial chemoembolization for patients with hepatocellular carcinoma and elevated lactate dehydrogenase is associated with low survival: a cohort study

  2022cites this paper
• Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization

  2022cites this paper
• Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model

  2021cites this paper
• Novel omics technology driving translational research in precision oncology.

  2021cites this paper
• Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3–<5 cm

  2021cites this paper
• Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma

  2021cites this paper
• Developments in predictive biomarkers for hepatocellular carcinoma therapy

  2020cites this paper
• Exploring DNA Methylation Profiles Altered in Cryptogenic Hepatocellular Carcinomas by High-Throughput Targeted DNA Methylation Sequencing: A Preliminary Study for Cryptogenic Hepatocellular Carcinoma

  2020cites this paper
• Exploring DNA Methylation Profiles Altered in Cryptogenic Hepatocellular Carcinomas by High-Throughput Targeted DNA Methylation Sequencing: A Preliminary Study for Cryptogenic Hepatocellular Carcinoma

  2020cites this paper
• Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients

  2020cites this paper
• Predictors of Recurrence of Hepatocellular Carcinoma after Transarterial Chemoembolization: Role of Hepatocyte Growth Factor

  2020cites this paper
• Exploring DNA Methylation Profiles Altered in Cryptogenic Hepatocellular Carcinomas by High-Throughput Targeted DNA Methylation Sequencing: A Preliminary Study for Cryptogenic Hepatocellular Carcinoma

  2020cites this paper
• Using Illumina Infinium HumanMethylation 450K BeadChip to explore genome-wide DNA methylation profiles in a human hepatocellular carcinoma cell line

  2018cites this paper
• Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization.

  2018cites this paper
• Validation of AFP Model as a Predictor of Response, Recurrence and Survival in HCC Patients Underwent Locoregional Treatment

  2018cites this paper
• Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis

  2018cites this paper
• Role of serum lactate dehydrogenase levels in evaluating efficacy of interventional therapy for hepatocellular carcinoma

  2018cites this paper
• Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease

  2018cites this paper
• Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization

  2017cites this paper
• Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma

  2017cites this paper
• Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

  2016cites this paper
• Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis, invasion, and stemness and is associated with poor clinical outcome

  2016cites this paper
• Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects

  2016cites this paper
• The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization

  2016cites this paper
• Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New

  2016influential citation
• HMGB1, nucleosomes and sRAGE as new prognostic serum markers after multiple trauma

  2016cites this paper
• Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma.

  2015cites this paper
• Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early- Stage Hepatocelluar Carcinoma.

  2015cites this paper
• C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review

  2015cites this paper
• Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

  2015cites this paper
• The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

  2015cites this paper
• Risk factors of recurrence among 471 Chinese patients with Budd-Chiari syndrome.

  2015cites this paper
• Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis.

  2015cites this paper
• Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights.

  2015cites this paper
• TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma

  2015cites this paper
• Liver cancer Liver cancer Immunogenic Cell Death Markers in Liver Cancer

  2015cites this paper
• The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

  2014cites this paper
• Immunogenic Cell Death Markers in Liver Cancer

  2014cites this paper
• Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma

  2014cites this paper
• Biomarkers in Esophageal Adenocarcinoma

  2014cites this paper
• Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression

  2014cites this paper
• Secondary use of existing public microarray data to predict outcome for hepatocellular carcinoma.

  2014cites this paper
• KIAA0101 mRNA overexpression in peripheral blood mononuclear cells acts as predictive marker for hepatic cancer

  2014cites this paper
• Prognostic value of serum γ-glutamyl transferase in unresectable hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization combined with conformal radiotherapy

  2014cites this paper
• Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria: systemic review and meta-analysis.

  2014cites this paper
• Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

  2013cites this paper
• DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy.

  2013cites this paper
• Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.

  2013cites this paper
• Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips

  2013cites this paper
• Circulating markers for prognosis of hepatocellular carcinoma.

  2013cites this paper
• Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy

  2013cites this paper
• Prognostic Role of C-Reactive Protein in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

  2013influential citation
• Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring

  2013cites this paper
• Mental Status Changes Postchemoembolization: The Role of Inflammatory Response

  2013cites this paper
• Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization

  2012cites this paper
• Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

  2012cites this paper
• The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management

  2012cites this paper